头孢丙烯治疗下呼吸道细菌性感染的临床评价

A randomized controlled clinical study on cefprozil and cefuroxime axetil in the treatment of low respiratory tract bacterial infections

目的 评价头孢丙烯治疗下呼吸道细菌性感染的有效性和安全性。方法 采用随机对照开放试验方法 ,选用头孢呋辛片为对照药 ,共治疗下呼吸道细菌感染 81例。头孢丙烯组 40例 ,5 0 0mg ;头孢呋辛组 41例 ,5 0 0mg ,均为每日两次 ,疗程 7～14d。结果 头孢丙烯组及头孢呋辛组有效率分别为 90 .0 %和 80 .5 % ,细菌阳性病例有效率分别为 82 .1%和 72 .4%。本试验共分离致病菌 5 7株 ,细菌清除率分别为 82 .1%和 75 .9%。安全性评价分别为 41例及 43例 ,不良反应发生率分别为 7.3%和 9.3%。经统计学处理差异无显著性 (P >0 .0 5 )。结论 采用头孢丙烯治疗急性下呼吸道细菌感染安全、有效。

OBJECTIVE: To evaluate the efficacy and safety of cefprozil in the treatment of bacterial infections of low respiratory tract. METHODS: A randomized controlled clinical study of cefprozil was conducted and the results were compared with those of cefuroxime axetil. Totally 81 patients were enrolled in the study. 40 patients received cefprozil 500 mg bid and 41 patients received cefuroxime axetil 500 mg bid. The duration of treatment was 7∼14 days in both groups. RESULTS: The overall efficacy were 90.0% for the cefprozil group and 80.5% for the cefuroxime axetil group, whereas the efficacy for bacterial were 82.1% and 72.4% respectively. 57 strains were isolated from the patients, the bacterial clearance were 82.1% and 75.9% respectively. The adverse drug reaction was evaluated in 41 cases of the cefprozil group and 43 cases of the cefuroxime axetil group. The adverse drug reaction rates were 7.3% and 9.3% respectively. The differences between two groups were no statistical significance. CONCLUSION: Cefprozil appeared to be a highly effective and safe agent for the treatment of lower respiratory tract bacterial infections.